Dr. Dasari on the Investigation of Fruquintinib in mCRC

Nageshwara Arvind Dasari, MD, associate professor, the Department of Gastrointestinal Medical Oncology, the Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the patient population observed in the phase 3 FRESCO-2 trial (NCT04322539) in metastatic colorectal cancer (mCRC).

The global, randomized, placebo-controlled FRESCO-2 trial randomly assigned patients 2:1 to received fruquintinib (Elunate) vs placebo, Dasari says. Fruquintinib was dosed at 5 mg daily for 3-weeks-on/1-week-off schedule, and both arms received best supportive care, Dasari adds. The primary end point of the trial was overall survival. Progression-free survival served as a key secondary end point, and other secondary end points included objective response rate, disease control rate, and safety, Dasari continues.

Heavily pretreated patients with mCRC who progressed on all available therapies, including chemotherapy, targeted therapies, trifluridine/tipiracil (TAS-102; Lonsurf), and regorafenib (Stivarga), were enrolled on the study, Dasari explains.